ResultsIQ

ResultsIQ › Latest results › Suraksha Diagnostic Limited

Suraksha Diagnostic Limited press release summary

NSE: SURAKSHA · BSE: 544293

Press release of 11 Nov 2026, summarised by AI from the filing.

The interview headline is corrected to "over 100 Crore total income in Q2" from "over 100 Crore net profit in Q2".

Key takeaways

  1. Headline The interview headline is corrected to "over 100 Crore total income in Q2" from "over 100 Crore net profit in Q2".
  2. Purpose The corrections are issued to clarify the actual financial performance of the company.
  3. Filing Company Secretary Shreya Arora issued the corrigendum to BSE and NSE for their records.

Original filing on BSE

Suraksha Diagnostic Limited Q2 FY27 results

As filed: Revenue ₹99.1 cr (+25% year on year), EBITDA ₹34.8 cr (+45% year on year), PAT ₹15.0 cr (+66% year on year), EBITDA margin 35.2% (+477 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹87.7 cr (+20% year on year), EBITDA ₹30.4 cr (+32% year on year), PAT ₹12.9 cr (+43% year on year), EBITDA margin 34.7% (+322 bps). Score 79 of 100, Above trend. EBITDA margin rose 322 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +19.8% in 30 days (Nifty 500: −3.4%).
  • Q4 FY26: Revenue ₹81.4 cr (+25% year on year), EBITDA ₹24.4 cr (+28% year on year), PAT ₹6.2 cr (−12% year on year), EBITDA margin 29.9% (+70 bps). Score 56 of 100, In line with trend. EBITDA margin rose 70 bps year on year. Tax rate 38%. Not enough history for a trend yet: scored on growth alone. Profit fell 15% from last quarter. Share price after the results: −16.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹77.7 cr (+29% year on year), EBITDA ₹23.2 cr (+29% year on year), PAT ₹7.2 cr (+21% year on year), EBITDA margin 29.8% (−19 bps). Score 70 of 100, Above trend. EBITDA margin fell 19 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −9.7% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹79.0 cr (+18% year on year), EBITDA ₹24.0 cr (0% year on year), PAT ₹9.0 cr (−10% year on year), EBITDA margin 30.4% (−544 bps). Score 36 of 100, Below trend. EBITDA margin fell 544 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −13.0% in 30 days (Nifty 500: −0.8%).
  • Q1 FY26: Revenue ₹70.0 cr, EBITDA ₹24.0 cr, PAT ₹10.0 cr, EBITDA margin 34.3%. Not scored. No result for the same quarter last year. Share price after the results: +0.9% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹64.0 cr, EBITDA ₹20.0 cr, PAT ₹8.0 cr, EBITDA margin 31.3%. Not scored. No result for the same quarter last year. Share price after the results: −1.7% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹59.0 cr, EBITDA ₹18.0 cr, PAT ₹6.0 cr, EBITDA margin 30.5%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Suraksha Diagnostic Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.